Free Republic
Browse · Search
News/Activism
Topics · Post Article

Skip to comments.

(Quick, easy, SARS tests are on the way) Discovery of SARS Antigenic Peptide
Businesswire ^ | 6-15-03

Posted on 06/16/2003 6:48:06 AM PDT by Logical Extinction

    ROCKVILLE, Md.--(BUSINESS WIRE)--June 16, 2003--Today, Vaxim, Inc., a Rockville Maryland based biopharmaceutical company, announced that it has successfully identified and synthesized a peptide from SARS viral proteins, named V-S26, which is confirmed to bind specifically with serum antibody from SARS recovered patients.

    With the focus of vast amount of resources of medical and biological institutes, the immediate need of effective SARS detection, treatment and prevention solutions remain pressing concerns that have not been answered by traditional techniques. Vaxim predicts that the company's novel approach by the quick identification of peptide that interacts with antibody specific to SARS viral proteins, will greatly shorten the process of developing effective diagnostic, vaccine and therapeutic products for the SARS.

    Vaxim has further successfully integrated V-S26 with the company's proprietary carrier platforms in developing the first SARS point-of-care test kit, named V-ST11, which is cost effective to produce and takes only 10 to 15 minutes to perform the required test. In contrary to existing testing methods employing traditional Lab test technologies like ELISA, Immunoflorescence assays, Cell Culture, and RT-PCR which takes more than 2 hours, V-ST11 test requires much less time and has the major advantage of being safe by using synthetic peptides for capturing SARS antibodies instead of requiring the use of SARS proteins or virus which can be highly contagious. The use of V-ST11 also does not require Lab environment, equipment and specially trained personnel.    


TOPICS: Front Page News; News/Current Events
KEYWORDS: antigenic; coronavirus; diagnostictest; peptide; sars; sarstest; vaxim; virus

Thank you America

Next step: Development of peptide fusion inhibitors
1 posted on 06/16/2003 6:48:06 AM PDT by Logical Extinction
[ Post Reply | Private Reply | View Replies]

To: Logical Extinction
God bless the free market and the U.S.A.

When we set our minds to it we can do anything. The speed of this is amazing...

2 posted on 06/16/2003 6:51:31 AM PDT by Damocles (sword of...)
[ Post Reply | Private Reply | To 1 | View Replies]

To: Damocles
They could very well be a foreign firm (or consortium including foreign interests).
3 posted on 06/16/2003 7:13:40 AM PDT by AmericanInTokyo (Kim Jong Il had ANOTHER bad underwear day . He found "decapitate" in his English-Korean dictionary.)
[ Post Reply | Private Reply | To 2 | View Replies]

To: AmericanInTokyo
When I do a google search for Vaxim I come up with a Japanese environmental science company. But www.vaxim.com takes you to this Rockville company. There's nothing about ownership on the website, but here's the company statement:

"Vaxim, Inc. is an emerging biotechnology company focused on the innovative technologies for delivery of gene, protein, peptide and small drug, today and into future. Vaxim is committed to the discovery of novel solutions and to serving as the leader in the effort to treat infectious diseases and cancers."
4 posted on 06/16/2003 7:23:56 AM PDT by Cicero (Marcus Tullius)
[ Post Reply | Private Reply | To 3 | View Replies]

To: Logical Extinction
Seems like we have seen the announcement of quite a few new tests, but we still see patients classified as supect or probable.
5 posted on 06/16/2003 7:40:37 AM PDT by per loin
[ Post Reply | Private Reply | To 1 | View Replies]

To: Logical Extinction
I'm sure they'll cash in with this test kit. Its a shame that so many suspected sars case individuals in china and taiwan may have been cremated without ever having been tested. Many more who may have sars and die even before antibodies are detectable. There is still need of an early test for sars which this product does not appear to be.
6 posted on 06/16/2003 7:41:18 AM PDT by dc-zoo
[ Post Reply | Private Reply | To 1 | View Replies]

To: per loin; aristeides; Prince Charles; FreepForever; CathyRyan; riri; Judith Anne; Dog Gone; ...
Seems like we have seen the announcement of quite a few new tests, but we still see patients classified as supect or probable.

Yep.

The problem with ALL antibody based tests so far has been the low number of antibodies to work with in the early stages of the disease. For this test to be the breakthrough we are hoping for, it must be EXTREMELY sensitive or it will have a high false negative rate.

Although this test has the appeal of simplicity (which is very important), I see nothing to indicate it will be sensitive enough to be useful early in the course of the disease. Hope I'm wrong.

Although I am skeptical, it seems significant enough to ping the usual suspects. My list is not as good as some. My apologies if I left someone out.

7 posted on 06/16/2003 8:12:26 AM PDT by EternalHope (Boycott everything French forever.)
[ Post Reply | Private Reply | To 5 | View Replies]

To: Logical Extinction
...identified and synthesized a peptide from SARS viral proteins, named V-S26, which is confirmed to bind specifically with serum antibody from SARS recovered patients.

The so-called "super spreaders" didn't produce antibodies did they?

The danger of rapid tests is that there is too much reliance on them. Rapid-strep test is a great example: if the test is positive and the patient can start treatment right away, that's great. But a negative test does not mean "no strep" and a swab may still may need to be sent out for culturing.

8 posted on 06/16/2003 8:23:01 AM PDT by TaxRelief
[ Post Reply | Private Reply | To 1 | View Replies]

To: _Jim
?
9 posted on 06/16/2003 8:46:12 AM PDT by Betty Jo
[ Post Reply | Private Reply | To 8 | View Replies]

To: Cicero; CathyRyan; Mother Abigail; Dog Gone; Petronski; per loin; riri; flutters; Judith Anne; ...
Rockville. Lots of biomedical research outfits on the Rte. 270 corridor.
10 posted on 06/16/2003 8:48:30 AM PDT by aristeides
[ Post Reply | Private Reply | To 4 | View Replies]

To: Logical Extinction
This virology is all very interesting but I wish someone would develop a test to detect interested and willing females. That would be a stock to own.
11 posted on 06/16/2003 9:20:06 AM PDT by vetvetdoug
[ Post Reply | Private Reply | To 1 | View Replies]

To: Logical Extinction
Next step: Development of peptide fusion inhibitors

If one wants to waste one's time on overhyped methods that don't work medically -- but bring in plenty of corporate welfare for scam artists pushing it.

12 posted on 06/16/2003 9:48:25 AM PDT by tallhappy
[ Post Reply | Private Reply | To 1 | View Replies]

To: Cicero
good groundwork. I'll now check google.co.jp and yahoo.co.jp, which will both search this firm primarily under Japanese domain addresses.
13 posted on 06/16/2003 10:07:38 AM PDT by AmericanInTokyo (Kim Jong Il had ANOTHER bad underwear day . He found "decapitate" in his English-Korean dictionary.)
[ Post Reply | Private Reply | To 4 | View Replies]

To: tallhappy
In many ways I agree with your very pessimistic evaluation of the role fusion inhibitors have played in healing.

However the science is sound. We know that like a lock needing two separate keys, once both sites on gp120 are bound by CD4 and one of the coreceptors, gp120 flips back out of the way, exposing the virus' previously hidden harpoon molecule, gp41. gp41 is then free to pierce the cell and reel it in close enough to allow virus-cell fusion. And no matter how much corporate greed or our personal faults as scientists and researchers have failed the ill and hurting - it is right that we try to stop this terrible binding (fusion).

I would urge you to moderate your position and look at some of the second generation FI's being developed.

Dr. Harrison of Harvard's Children's Hospital is working very hard to inhibit fusion in the dengue virus.

While it is true that we have all fallen short of the Glory, the fight is noble and most of the warriors are among the finest men and women I have ever known.
14 posted on 06/16/2003 8:53:19 PM PDT by Logical Extinction (Reality is often much more frightening than fiction...)
[ Post Reply | Private Reply | To 12 | View Replies]

To: per loin
It might be wise to be a bit sceptical of case classification on this disease.
15 posted on 06/16/2003 8:56:22 PM PDT by Logical Extinction (Reality is often much more frightening than fiction...)
[ Post Reply | Private Reply | To 5 | View Replies]

To: dc-zoo
I agree.

However this tool may allow us to gauge quite a few paramaters.
16 posted on 06/16/2003 9:03:40 PM PDT by Logical Extinction (Reality is often much more frightening than fiction...)
[ Post Reply | Private Reply | To 6 | View Replies]

To: vetvetdoug

17 posted on 06/16/2003 9:41:33 PM PDT by Logical Extinction (Reality is often much more frightening than fiction...)
[ Post Reply | Private Reply | To 11 | View Replies]

To: Logical Extinction
I got a 66' Mustang GT Convertible, just doesn't seem to have the attraction that car does....Good idea though.
18 posted on 06/17/2003 5:39:55 AM PDT by vetvetdoug
[ Post Reply | Private Reply | To 17 | View Replies]

To: Logical Extinction
Sure.

I think simple vaccination would be much more effective for SARS.

Why not address the flu first and foremost using FI? By far more is known about the fusion mechanism for that virus and it is a disease people get all the time.

19 posted on 06/17/2003 9:23:18 AM PDT by tallhappy
[ Post Reply | Private Reply | To 14 | View Replies]

To: tallhappy
There is no question that a vaccine would be the ideal solution.

Until that time, however, we need agents that will mitigate the course of this disease in the more severely affected.

As to influenza:

Amantadine and rimantadine interfere with the fusion function of hemagglutinin, (a necessary step during viral penetration of host cells).

When used to treat active influenza A disease, amantadine or
rimantadine will shorten the clinical course.
20 posted on 06/18/2003 7:32:43 AM PDT by Logical Extinction (Reality is often much more frightening than fiction...)
[ Post Reply | Private Reply | To 19 | View Replies]

To: Logical Extinction
Are most FI's screened? Or are people trying to design them?

Have all the local anesthetics and related ion channel binding molecules been screened?

21 posted on 06/18/2003 10:05:08 AM PDT by tallhappy
[ Post Reply | Private Reply | To 20 | View Replies]

To: per loin
Seems like we have seen the announcement of quite a few new tests, but we still see patients classified as supect or probable.

"Please allow three to six weeks for delivery"

THEN there is the problem of getting local health authorites AWARE of these 'test kits' in the first place, the ramp-up by the manufacturer for 'production' quanties (no Scarlet, there is no giant wharehouse in the sky from which all products simply 'flow' to the stock shelves of your local Wal-Mart) ...

22 posted on 06/18/2003 10:14:25 AM PDT by _Jim
[ Post Reply | Private Reply | To 5 | View Replies]

To: Betty Jo
"?"

Do you belive that crap (yet another SARS test)?

This is the beginning of the end to your supposed Chinese-engineered world-threatening virus!

All you'll have left is your turban-wearing furry 'terrs' carrying mpox around ...

23 posted on 06/18/2003 10:17:54 AM PDT by _Jim
[ Post Reply | Private Reply | To 9 | View Replies]

To: _Jim
Nope. The big problem with these tests is that none of them seem to work in the early stages of an infection.
24 posted on 06/18/2003 2:54:38 PM PDT by per loin
[ Post Reply | Private Reply | To 22 | View Replies]

To: tallhappy
Excellent question,

OLD SCHOOL

The interactions between the viral envelope glycoprotein gp120, its cellular receptor CD4, and the specific co-receptor are part of the early events occurring during cell infection by HIV-1. Antagonists of HIV-1 replication at the entry level, via blockade of attachment, gp120/CD4/co-receptor interactions, or gp41 structural changes, represent a potential source for HIV-1 treatment.

Synthetic combinatorial libraries (SCLs) made up of thousands to millions of compounds are a powerful approach for the development of such antagonists.

2 recombinant vaccinia virus-based assays mimicking a T-cell line-tropism (IIIb-X4) and macrophage-tropism (JRFL-R5) have been developed to quantify the inhibition of the fusogenic activity of HIV-1 envelope glycoproteins. The expression of Lac Z from a reporter gene upon fusion was used to measure colorimetrically the fusion of target and effector cells. 2 peptide SCLs were screened in these assays to develop fusion inhibitors: a l-amino acid nonapeptide and a d-amino acid decapeptide SCLs. The inhibitory activities of the identified peptides were assayed in the vaccinia virus-based fusion and replication assays using different laboratory virus strains as well as clinical isolates.

Following the screening of the 2 SCLs in the X4 fusion system, 38 d-amino acid decapeptides and 44 l-amino acid nonapeptides were generated and their inhibitory activities determined. 5 nonapeptides exhibited inhibitory activity with IC90 values lower than 10 µg/mL, while the most active decapeptides have IC90 values around 25 µg/mL when tested in the X4 fusion system. Lower activity was observed in the R5 fusion system. These peptides have similar efficacy in the inhibition of virus replication (IC90 values = 10 to 50 µg/ml in an assay using IIIb/X4 virus and between 50 and 80% inhibition at 25 µg/mL in assays using other X4, R5, and X4R5 virus strains).

Studies toward the understanding the peptides mechanism and target of inhibition have been started.

These studies allowed the rapid identification of novel HIV fusion inhibitors that represent leads for new therapies targeting the entry of HIV-1, and useful tools to further study and enhance the understanding of the fusion process.



NEW WAVE

A novel test has been designed to allow rapid screening of HIV inhibitors The test is based on the measurement of cell-to-cell fusion mediated by the HIV envelope. The HIV fusion test has a high throughput, it is semi-automated and takes 10 to 12 hours maximum including read-out of data and statistical analysis.

It is thus possible to test a large number of samples/inhibitors at the same time. The fusion process can be specifically targeted as the read-out exclusively measures cell-to-cell fusion and does not depend on viral replication or activation of reporter genes.

The test is very versatile in that virtually any envelope sequence from distinct HIV isolates can be used for the donor cell.

Expression of envelope glycoproteins from different viral strains is normalised and there is no bias due to the replication potential of the original HIV-isolate which could result in variations of expression levels of the envelope. Moreover, various cell types including primary cells can be used as target cells.

It is possible to screen for inhibitory molecules targeted against either the HIV envelope glycoproteins gp120 or gp41, against the CD4 receptor or the chemokine receptors. Using cell lines that express only one given co-receptor, molecules can be designed against either CXCR4 or CCR5 or any other receptor molecule. The efficacy of such drugs can subsequently be tested in fusion assays on primary cells such as peripheral blood lymphocytes or macrophages.

This test is also suited for the development of inhibitors of the human T-cell leukemia virus type 1 (HTLV-1).





IN AN ALCHEMY OF LIGHT

Both the changer and the changed
Are found...
25 posted on 06/18/2003 6:00:04 PM PDT by Logical Extinction (Reality is often much more frightening than fiction...)
[ Post Reply | Private Reply | To 21 | View Replies]

To: All
First you release SARS into the world, and then you sell billions of SARS test kits and billions of SARS vaccines.
26 posted on 06/20/2003 4:06:48 PM PDT by TaxRelief (The Microsoft Upgrade Theory.......)
[ Post Reply | Private Reply | To 24 | View Replies]

Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.

Free Republic
Browse · Search
News/Activism
Topics · Post Article

FreeRepublic, LLC, PO BOX 9771, FRESNO, CA 93794
FreeRepublic.com is powered by software copyright 2000-2008 John Robinson